← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Vericel Corp VCEL $2.06B	272	-5	-2%	$2.35B
27	27 Twist Bioscience TWST $8.73B	244	-19	-7%	$2.62B
28	28 Adaptive Biotechnologies ADPT $3.84B	242	+17	+8%	$1.73B
29	29 GeneDx Holdings WGS $1.88B	231	+6	+3%	$2.91B
30	30 Myriad Genetics MYGN $393M	221	-7	-3%	$480M
31	31 ARK Genomic Revolution ETF ARKG $1.97B	217	0	0%	$528M
32	32 Beam Therapeutics BEAM $2.41B	217	-21	-9%	$1.84B
33	33 Legend Biotech LEGN $3.66B	211	+3	+1%	$3B
34	34 Pacific Biosciences PACB $532M	207	-18	-8%	$246M
35	35 DELISTED Arcellx ACLX	202	+5	+3%	$4.01B
36	36 CareDx CDNA $3.27B	197	-21	-10%	$1.05B
37	37 Rocket Pharmaceuticals RCKT $244M	196	-40	-17%	$233M
38	38 DELISTED BioLife Solutions BLFS	194	+6	+3%	$1.07B
39	39 Editas Medicine EDIT $366M	194	-1	-0.5%	$90.9M
40	40 Wave Life Sciences WVE $615M	176	-20	-10%	$903M
41	41 DELISTED Verve Therapeutics VERV	175	-16	-8%	$819M
42	42 Fulgent Genetics FLGT $552M	167	-9	-5%	$323M
43	43 Ginkgo Bioworks DNA $688M	166	-1	-0.6%	$375M
44	44 Arbutus Biopharma ABUS $842M	162	-5	-3%	$365M
45	45 Standard BioTools LAB $250M	160	+15	+10%	$337M
46	46 Regenxbio RGNX $461M	159	-5	-3%	$345M
47	47 Allogene Therapeutics ALLO $449M	158	-13	-8%	$208M
48	48 Sana Biotechnology SANA $692M	155	-6	-4%	$398M
49	49 Maravai LifeSciences MRVI $1.01B	150	-34	-18%	$313M
50	50 Taysha Gene Therapies TSHA $1.2B	150	+23	+18%	$595M